PDLI

Intends to File Preliminary Proxy Statement and Provides Overview of the Case for Shareholder-Driven Change at Lyft Following Years of Value Destruction Engine Capital LP (together with its affiliates, "Engine" or "we"), which owns approximately one percent of the outstanding common shares of Lyft, Inc. (NASDAQ:LYFT) ("Lyft" or the "Company"), today announced that it is filing a preliminary proxy statement in connection with its nomination of two highly qualified and independent candidates – Alan L. Bazaar and Daniel B. Silvers – for election to the Company's Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders (the "Annual Meeting"). Arnaud Ajdler, Founder and Port

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut

SC TO-I/A - PDL BIOPHARMA, INC. (0000882104) (Subject)

SC 13G/A - PDL BIOPHARMA, INC. (0000882104) (Subject)

SC 13G/A - PDL BIOPHARMA, INC. (0000882104) (Subject)

EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)

EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)

EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)

EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)

EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)

EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)

EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)

4 - PDL BIOPHARMA, INC. (0000882104) (Issuer)

POS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)

POS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)

POS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)

POS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)

POS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)

POS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)

POS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)

EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)

EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)

POS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)

POS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)